Dimed Distribuidora de Medicamentos Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Julio Mottin Neto
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | no data |
CEO ownership | 0.2% |
Management average tenure | no data |
Board average tenure | no data |
Recent management updates
Recent updates
Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Nov 17Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital
Nov 04These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively
Jul 12Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings
May 27Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital
Apr 15Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly
Mar 25The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence
Jan 06Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
Oct 23Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return
Aug 15CEO
Julio Mottin Neto
no data
Tenure
Mr. Julio Ricardo Mottin serves as Chief Executive Officer of Dimed S.A. Distribuidora de Medicamentos and served as its Deputy Chief Executive Officer and served as its Director.
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/05 03:49 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dimed S.A. Distribuidora de Medicamentos is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Frederico Mendes | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
Marcio Osako | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |
Francisco Navarrete | Bradesco S.A. Corretora de Títulos e Valores Mobiliários |